Our research is focused at exploring the role of the innate and adaptive immunity in the pathogenesis of non-ischemic heart failure with main interest in inflammatory cardiomyopathy, diabetic cardiomyopathy and heart failure with preserved ejection fraction. The relevance of the cardiosplenic axis, i.e. homing of immune cells towards the heart and their subsequent involvement in cardiac remodelling is studied. Our further interest is the characterization of interactions among immune cells and cardiac endothelial cells, cardiac fibroblasts, and cardiomyocytes, as well as the reciprocal interactions among the cardiac cells.
The second focus of our research lies on evaluating the potential of immunomodulating strategies to treat or prevent inflammatory, diabetic cardiomyopathy or heart failure with preserved ejection fraction. In this regard, we investigate the potential of systemic delivery of cardiac-derived proliferating cells (CardAPs; cells isolated and characterized at the BCRT in conjunction with platform C, Tissue Engineering and D, Immune System), mesenchymal stromal cells, or T regulatory cells as well the potential of immunomodulatory pharmaca.
With the aim to translate our findings into the clinic, our observations in patients and patients material (endomyocardial biopsies, serum, circulating mononuclear cells) are further validated in in vivo and in vitro models and vice versa. Therefore, the group of experimental cardioimmunology is strongly interconnected with the cardioproteomics and clinical